Stock analysis, trade plans, and proprietary indicators by Trend Edge.
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. Read full Trend Edge analysis →
| Current Price | $97.33 |
|---|---|
| Market Cap | $5.91B |
| Float | 52.5M |
| Shares Outstanding | 61.0M |
| P/E (Forward) | 2,000.00 |
| Price/Sales (TTM) | 10.38 |
| vs. Analyst Target | +48.1% to analyst PT |
| Profit Margin | -140.24% |
| Operating Margin (TTM) | -39.51% |
| Revenue (TTM) | $570M |
| Dividend Rate | None |
| Analyst Target Price | $144.15 (10 analysts) |
| Year | Revenue | Net Income | Gross Profit | EBITDA |
|---|---|---|---|---|
| 2020 | $11.0M | -$103M | -$623,000 | -$102M |
| 2021 | $19.1M | -$84.0M | $17.2M | -$65.4M |
| 2022 | $77.1M | -$136M | $64.7M | -$123M |
| 2023 | $186M | -$163M | $139M | -$136M |
| 2024 | $337M | -$87.9M | $255M | -$49.0M |
| 2025 | $521M | -$23.4M | $421M | $17.2M |
| Quarter | Revenue | Net Income |
|---|---|---|
| Jun 2025 | $128M | -$5.9M |
| Sep 2025 | $133M | $2.9M |
| Dec 2025 | $149M | -$5.7M |
| Mar 2026 | $160M | -$790M |
| Insider Ownership | 1.4% |
|---|---|
| Institutional Ownership | 114.8% |
| Short Float | 16.0% |
| % of All Funds Holding | 3.53% |
| Number of Funds Holding | 290 |
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
| Timeframe | SMA | Value | Trend Context |
|---|---|---|---|
| Weekly | 10-Week SMA | $96.91 | Near-term / short-term trend |
| Weekly | 40-Week SMA | $84.90 | Medium-term trend |
| Weekly | 80-Week SMA | $66.31 | Cyclical trend (business cycle) |
| Weekly | 200-Week SMA | $43.41 | Secular trend (multi-year) |
| Monthly | 10-Month SMA | $85.44 | Near-term monthly trend |
| Monthly | 20-Month SMA | $65.62 | Medium-term monthly trend |
| Monthly | 40-Month SMA | $47.45 | Secular monthly trend |
Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
| Price Level | Type | Volume Ratio | Age |
|---|---|---|---|
| $103.00 | resistance | 1.03x | 2 months ago |
| $80.00 | support | 1.33x | 3 months ago |
| $52.00 | support | 1.91x | 8 months ago |
| $45.00 | support | 1.03x | 10 months ago |
| $34.50 | support | 1.25x | 21 months ago |
| Timeframe | Avg Return | Median | Win Rate | Best | Worst |
|---|---|---|---|---|---|
| Gap | 1.77% | 0.89% | 67.86% | 9.02% | -2.96% |
| 1 Day | 2.90% | 2.46% | 67.86% | 16.22% | -6.50% |
| 1 Week | 1.79% | 1.37% | 57.14% | 21.43% | -19.88% |
| 2 Weeks | 4.00% | 1.98% | 60.71% | 29.56% | -25.94% |
| 1 Month | 8.30% | 6.28% | 62.96% | 45.51% | -25.42% |
Next earnings: July 25, 2026 (58 days away)
Insufficient historical data for monthly seasonality analysis (requires 7+ years of data).
| Day | Avg Return | Win Rate | Samples |
|---|---|---|---|
| Monday | 0.41% | 50.9% | 322 |
| Tuesday | 0.04% | 53.5% | 357 |
| Wednesday | 0.03% | 49.1% | 352 |
| Thursday | 0.21% | 49.6% | 345 |
| Friday | 0.39% | 52.3% | 346 |
Institutional holder breakdown coming soon.
Total institutional ownership: 114.8%
Total insider ownership: 1.4%
Founder-led management: Christopher Peetz (Chief Executive Officer)
| Total Filings | 38 |
|---|---|
| Net Value | -$16.4M |
| Net Shares Change | 357,216 |
| % of Float | 0.7% |
| C-Suite Filings | 23 |
| Clusters Detected | 4 |
| Name | Title | Net Value | Filings | Activity |
|---|---|---|---|---|
| Heron Patrick J | +$9.0M | 1 | 1 buy | |
| Peetz Christopher | CHIEF EXECUTIVE OFFICER | -$3.8M | 1 | 1 sell |
| Radovich Peter | PRESIDENT AND COO | -$2.1M | 3 | 3 sell |
| Quan Joanne | CHIEF MEDICAL OFFICER | -$1.5M | 3 | 3 sell |
| BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | -$670,242.957 | 1 | 1 sell |
| Howe Jolanda | SVP, GLOBAL CONTROLLER | -$435,239.423 | 1 | 1 sell |
| Period | Filings | Insiders | Net Value | Seniority |
|---|---|---|---|---|
| 2025-08-08 – 2025-08-12 | 4 | 3 | -$4.9M | 4 C-suite |
| 2026-01-15 – 2026-01-27 | 12 | 7 | +$5.8M | 10 C-suite |
| 2026-02-03 – 2026-02-17 | 4 | 4 | -$1.5M | 3 C-suite |
| 2026-03-17 – 2026-03-17 | 6 | 6 | -$7.2M | 5 C-suite |
| Date | Insider | Title | Net Value | Price After |
|---|---|---|---|---|
| 2026-03-17 | Radovich Peter | PRESIDENT AND COO | -$1.5M | Transaction at $91.98, now +5.8% |
| 2026-03-17 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | -$3.8M | Transaction at $91.98, now +5.8% |
| 2026-03-17 | Quan Joanne | CHIEF MEDICAL OFFICER | -$670,242.957 | Transaction at $91.98, now +5.8% |
| 2026-03-17 | Howe Jolanda | SVP, GLOBAL CONTROLLER | -$435,239.423 | Transaction at $91.98, now +5.8% |
| 2026-03-17 | BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | -$670,242.957 | Transaction at $91.98, now +5.8% |
| 2026-01-27 | Heron Patrick J | +$9.0M | Transaction at $68.48, now +42.1% |
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Mirum Pharmaceuticals Inc (MIRM) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.
Get the full AI Consult analysis for MIRM on Trend Edge →